Related references
Note: Only part of the references are listed.Implications of Plasma Δ9-Tetrahydrocannabinol, 11-Hydroxy-THC, and 11-nor-9-Carboxy-THC Concentrations in Chronic Cannabis Smokers
Erin L. Karschner et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2009)
Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint
Stefan W. Toennes et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2008)
Pharmacokinetics of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects
A. Glaz-Sandberg et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Pharmacokinetic properties of Δ9-tetrahydrocannabinol in serum and oral fluid
Gerold F. Kauert et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2007)
Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use
F Musshoff et al.
THERAPEUTIC DRUG MONITORING (2006)
Pharmacokinetics and pharmacodynamics of cannabinoids
F Grotenhermen
CLINICAL PHARMACOKINETICS (2003)
Ethanol increases plasma Δ9-tetrahydrocannabinol (THC) levels and subjective effects after marihuana smoking in human volunteers
SE Lukas et al.
DRUG AND ALCOHOL DEPENDENCE (2001)
Share Paper
